MARKET

AXNX

AXNX

Axonics Inc
NASDAQ
66.71
+0.07
+0.11%
Opening 09:55 04/25 EDT
OPEN
66.65
PREV CLOSE
66.64
HIGH
66.75
LOW
66.65
VOLUME
30.57K
TURNOVER
0
52 WEEK HIGH
69.68
52 WEEK LOW
47.59
MARKET CAP
3.40B
P/E (TTM)
-537.9839
1D
5D
1M
3M
1Y
5Y
BOSTON SCIENTIFIC CORP- SEES NET SALES GROWTH FOR Q2 OF 2024, TO BE IN A RANGE OF ABOUT 10 TO 12 PERCENT ON AN ORGANIC BASIS
Reuters · 1d ago
BOSTON SCIENTIFIC CORP- SEES Q2 EPS ON A GAAP BASIS IN A RANGE OF $0.35 TO $0.37 AND ADJUSTED EPS, OF $0.57 TO $0.59
Reuters · 1d ago
Press Release: Boston Scientific Announces -4-
Earnings per Share is a measure of Boston Scientific's performance. The company expects to report earnings per share for the year ending September 30, 2024. The company does not expect to release a full year 2024 earnings estimate until after the end of the year. The Company's results are calculated on a GAAP basis.
Dow Jones · 1d ago
Press Release: Boston Scientific Announces Results for First Quarter 2024
Boston Scientific Corporation generated net sales of $3.856 billion during the first quarter of 2024. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million. First quarter sales grew 13.8 percent on a reported basis and 13.1 percent on an organic basis. The initial U.S. Launch of the FARAPULSE(TM) Pulsed Field Ablation System.
Dow Jones · 1d ago
Wells Fargo Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
TipRanks · 2d ago
Weekly Report: what happened at AXNX last week (0415-0419)?
Weekly Report · 3d ago
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
Boston Scientific Corporation said it recalled Obsidio Embolic by issuing a correction. The FDA has identified this as a Class I recall, the most severe type of recall. Eleven incidents were reported, seven injuries, and two deaths related to this issue. The company has issued a recall for around 1,600 devices.
Benzinga · 04/18 14:02
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
TipRanks · 04/17 08:00
More
About AXNX
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.

Webull offers Axonics Inc stock information, including NASDAQ: AXNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXNX stock methods without spending real money on the virtual paper trading platform.